Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.
Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.
An enzyme therapy may prevent skeletal abnormalities associated with the genetic disorder neurofibromatosis type-1, Vanderbilt investigators have discovered.
Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies.
Insights into the workings of DNA damage response proteins such as SMARCAL1 could suggest new ways to improve genome integrity and prevent cancer.
A genetic variant is associated with toxicity of the chemotherapy drug melphalan, and could guide individualized dosing for the medication.